DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Beemer-Langer syndrome — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBeemer-Langer syndrome maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for beemer-langer syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NIMA related kinase 1 (NEK1) — NEK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2-amino-4-methyl-thiazol-5-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4B9D · 1.9 Å · ligand [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO-PHENYL)-AMINE (CK7). Experimental structure, not a prediction.
What the evidence adds up to
Beemer-Langer syndrome is a lethal short rib osteochondrodysplasia with autosomal recessive inheritance. A 1991 report describes an infant girl with hydrops, macrocephaly, flat face, hypertelorism, broad nasal bridge, median cleft lip and alveolar ridge, grooved palate, accessory frenula, small tongue, milia, severe rib and limb shortness, brachydactyly, talipes equinovarus, Dandy-Walker malformation, accessory spleen, unfixed mesentery, ectopic pancreas, and renal cysts. The authors note that polydactyly is usually absent and that the severe rib and limb shortness distinguishes the condition from orofaciodigital syndromes. A 2000 report adds a male infant born at 37 weeks with hydrops fetalis, facial and visceral abnormalities, short ribs, and short limbs without polydactyly, plus less frequently described arachnoid cysts of the brain and short intestines.
No drug treatment is mentioned in any of these abstracts. The 2018 abstract concerns Cornelia de-Lange syndrome, a different disorder, and does not discuss Beemer-Langer syndrome or any therapeutic intervention. Across the Beemer-Langer reports, the condition is consistently described as lethal, with no survival data or response rates provided because no treatment was attempted or reported.
The abstracts provide no information on molecular genetics, biochemical markers, or any preclinical or clinical testing of compounds. What is missing is any investigation into the underlying genetic mechanism that might be targetable, any animal model work, any drug screening effort, and any clinical trial design. Without funding for basic research into the pathogenesis and without patient stratification by genotype, no repurposing candidate can be proposed from this evidence.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1991 · 26 citations
Beemer‐Langer syndrome with manifestations of an orofaciodigital syndrome
AbstractWe report on an infant girl with hydrops, macrocephaly, high forehead, flat face, hypertelorism, broad nasal bridge, median cleft lip and alveolar ridge, grooved palate, accessory frenula, small tongue, milia, severe rib and limb shortness, brachydactyly, talipes equinovarus, Dandy-Walker malformation, accessory spleen, unfixed mesentery, ectopic pancreas, and renal cysts. This patient resembles seven previously reported patients with the Beemer-Langer syndrome, a distinct lethal short rib syndrome characterized by hydrops, markedly short ribs and limbs, median cleft lip with or without cleft palate, flat face, and macrocephaly. Polydactyly is usually absent. Our patient's oral anomalies suggest an orofaciodigital syndrome, but the severe rib and limb shortness distinguish it from those disorders.
Pediatric and Developmental Pathology · 2000 · 3 citations
New Case of Beemer-Langer Syndrome
AbstractWe present the case of a male infant born at 37 weeks gestation with multiple congenital anomalies, including hydrops fetalis, facial and visceral abnormalities, short ribs, and short limbs without polydactyly. We believe that this represents a further case of the Beemer-Langer syndrome, a relatively recently described form of lethal osteochondrodysplasia with an autosomal recessive mode of inheritance. This case also showed some less frequently described anomalies, including arachnoid cysts of the brain and short intestines.
Journal of Indian Academy of Oral Medicine and Radiology · 2018 · 3 citations · open access
Cornelia de-Lange syndrome - A case report
AbstractCornelia de-Lange syndrome (CdLS) is a rare multisystem developmental disorder characterized by psychomotor retardation and delayed growth associated with a series of malformations, including facial dysmorphia, upper-extremity malformations, hirsutism, cardiac defects, and gastrointestinal abnormalities. There is no definitive biochemical or chromosomal marker for the prenatal diagnosis of syndrome so it is important for the clinician to know etiopathological aspects and characteristic features to provide health care and help improve the quality of life of affected individuals.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
